Osman, Karen L.
Jefferies, Johanna M. C.
Woelk, Christopher H.
Devos, Nathalie
Pascal, Thierry G.
Mortier, Marie-Cécile
Devaster, Jeanne-Marie
Wilkinson, Tom M. A
Cleary, David W.
Clarke, Stuart C.
Alnajar, J.
Anderson, R.
Aris, E.
Ballou, W. R.
Barton, A.
Bourne, S.
Caubet, M.
Cohet, C.
Coombs, N.
Devine, V.
Dineen, E.
Elliott, T.
Gladstone, R.
Harden, S.
Kim, V.
Vela, S. Mesia
Moris, P.
Ostridge, K.
Peeters, M.
Schoonbroodt, S.
Staples, K. J.
Tuck, A.
Welch, L.
Weynants, V.
Williams, A. P.
Williams, N.
Wojtas, M.
Wootton, S.
,
Funding for this research was provided by:
GlaxoSmithKline (NCT01360398, NCT01360398, NCT01360398, NCT01360398, NCT01360398, NCT01360398, NCT01360398)
Article History
Received: 12 June 2018
Accepted: 19 September 2018
First Online: 3 October 2018
Competing Interests
: K.O. was funded by G.S.K. to conduct this study as part of a studentship. T.M.A.W. has received reimbursement for travel and meeting attendance from Boehringer Ingelheim and AstraZeneca, outside of the submitted work. S.C. reports grants from G.S.K., during the conduct of the study; grants from Pfizer, outside the submitted work. N.D., T.P. and J.M.D. are employees of the G.S.K. group of companies, and own shares/restricted shares in the G.S.K. group of companies. D.W.C. and T.M.A.W. received an institutional grant from the G.S.K. group of companies to conduct this study. The other authors have nothing to disclose.